Literature DB >> 16461208

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention.

D Lavanchy1.   

Abstract

Worldwide, hepatitis B virus (HBV) is the most common among those hepatitis viruses that cause chronic infections of the liver in humans, and it represents a global public health problem. Chronic hepatitis caused by HBV is the major cause of hepatocellular carcinoma (HCC) worldwide, and remains therefore a major public health problem globally. This fact is related to both the continuing occurrence of frequent new infections and to the presence of a large reservoir of persons chronically infected, which may develop severe and fatal complications of chronic liver disease. Hepatitis B and all of the complications resulting from it, as well hepatitis D (HDV) and its complications, are globally preventable by hepatitis B vaccination, and therefore elimination of HBV transmission and of new acute and chronic infections is a feasible goal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16461208     DOI: 10.1016/s1386-6532(05)00384-7

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  139 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

2.  Simultaneous genotyping and quantification of hepatitis B virus for genotypes B and C by real-time PCR assay.

Authors:  Yao Zhao; Xiu-Yu Zhang; Jin-Jun Guo; Ai-Zhong Zeng; Jie-Li Hu; Wen-Xiang Huang; You-Lan Shan; Ai-Long Huang
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

Review 3.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

4.  Development of Fok-I based nested polymerase chain reaction-restriction fragment length polymorphism analysis for detection of hepatitis B virus X region V5M mutation.

Authors:  Hong Kim; Seok-Hyun Hong; Seoung-Ae Lee; Jeong-Ryeol Gong; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

5.  Presence of anti-HBs antibodies in blood donors 18-22 years after vaccination and implications for the selection of candidates for plasmapheresis for the production of hyperimmune plasma.

Authors:  Massimo De Paschale; Stefania Latella; Arianna Gatti; Bruno Brando; M Teresa Manco; Luisa Belvisi; Debora Cagnin; Teresa Cerulli; Alessia Paganini; Maurizio Macchi; Pierangelo Clerici
Journal:  Blood Transfus       Date:  2015-10-29       Impact factor: 3.443

6.  Recent epidemiological and clinical features of acute hepatitis B in a single center of China.

Authors:  Xiaohong Chen; Chengtao Fu; Jia Liu; Lei Shan; Chenglin Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.

Authors:  Elena Lomonosova; Jil Daw; Aswin K Garimallaprabhakaran; Nana B Agyemang; Yashkumar Ashani; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

8.  Male-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients.

Authors:  Seoung-Ae Lee; Ki-Jeong Kim; Dong-Won Kim; Bum-Joon Kim
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

Review 9.  Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission.

Authors:  Naichaya Chamroonkul; Teerha Piratvisuth
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

10.  Perinatal hepatitis B prevention program in Shandong Province, China. Evaluation and progress.

Authors:  Li Zhang; Stephen Ko; Jingjing Lv; Feng Ji; Bingyu Yan; Fujie Xu; Aiqiang Xu
Journal:  Hum Vaccin Immunother       Date:  2014-11-06       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.